Why the study?
Does continuation of anticoagulant or antiplatelet therapy increase hemorrhagic complications in patients undergoing transrectal ultrasound-guided prostate biopsies?
Does continuation of anticoagulant or antiplatelet therapy increase hemorrhagic complications in patients undergoing transrectal ultrasound-guided prostate biopsies?
A systematic review was conducted to assess the safety of continuing anticoagulation or antiplatelet therapy during transrectal ultrasound-guided prostate biopsies.
Informs periprocedural anticoagulation decisions in prostate biopsy; extends synthesized evidence on hemorrhagic complications.
Historically it was thought that there was an increase in the hemorrhagic complications with regards to performing transrectal ultrasound-guided prostate biopsies on patients receiving anticoagulation/antiplatelet therapy. Current literature supports continuation of anticoagulation/antiplatelet therapy without additional morbidity. We sought to systematically assess the current published evidence regarding the continuation of anticoagulation/antiplatelet therapy during transrectal ultrasound-guided prostate biopsies and comment on their clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Raheem et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Current Urology